Citizens Jmp Increases Abivax (NASDAQ:ABVX) Price Target to $131.00

Abivax (NASDAQ:ABVX) had its target price upped by equities researchers at Citizens Jmp from $114.00 to $131.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s target price would suggest a potential upside of 18.21% from the company’s current price.

Other equities research analysts also recently issued research reports about the company. Guggenheim upped their price target on Abivax from $101.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research report on Wednesday, October 8th. JMP Securities raised their target price on shares of Abivax from $95.00 to $114.00 and gave the company a “market outperform” rating in a report on Thursday, September 25th. Morgan Stanley boosted their price target on shares of Abivax from $71.00 to $101.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Finally, Wall Street Zen downgraded shares of Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.45.

Abivax Stock Performance

Shares of ABVX stock opened at $110.82 on Tuesday. The firm has a 50 day moving average of $107.85 and a two-hundred day moving average of $70.37. The stock has a market capitalization of $8.64 billion, a PE ratio of -64.06 and a beta of 0.48. The company has a quick ratio of 0.77, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. Abivax has a 52 week low of $4.77 and a 52 week high of $138.49.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The firm had revenue of ($4.92) million during the quarter. On average, research analysts predict that Abivax will post -2.83 EPS for the current fiscal year.

Institutional Trading of Abivax

Hedge funds and other institutional investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC boosted its position in shares of Abivax by 4,612.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after purchasing an additional 369 shares during the period. First Horizon Corp purchased a new stake in Abivax in the third quarter valued at approximately $36,000. Bank of America Corp DE boosted its holdings in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after acquiring an additional 1,990 shares during the period. Hantz Financial Services Inc. acquired a new stake in shares of Abivax in the third quarter valued at approximately $52,000. Finally, Cubist Systematic Strategies LLC grew its position in shares of Abivax by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after acquiring an additional 2,595 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.